Evidence map›Paper›PMID 25886675›Full record

ReviewCanadian journal of psychiatry. Revue canadienne de psychiatrie2015

What does schizophrenia teach us about antipsychotics?

Gary Remington, Ofer Agid, George Foussias, Gagan Fervaha, Hiroyoshi Takeuchi, Jimmy Lee, Margaret Hahn

Abstract readReview
PubMed Full text at PMC
In one paragraph

Review in Canadian journal of psychiatry. Revue canadienne de psychiatrie, 2015. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 3 papers.

0numbers the graph read from it
0cells of the map it votes in
3citing papers in PubMed
0.8field-weighted citation impact, top 28% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

3 citing papers in PubMed, 9 citations in OpenAlex.

  1. Review
  2. Review
  3. The 10th Anniversary of the Eli Lilly Chair of Schizophrenia from the University of Montreal.Canadian journal of psychiatry. Revue canadienne de psychiatrie · 2015
    Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

7 authors at 4 institutions in 3 countries.

Gary RemingtonProfessor, Department of Psychiatry, University of Toronto, Toronto, Ontario; Lead, Subspecialty Clinics, Schizophrenia Program, Centre for Addiction and Mental Health, Toronto, Ontario; Senior Scientist, Campbell Family Mental Health Research Institute, Toronto, Ontario; Faculty, Institute of Medical Science, Toronto, Ontario.
Ofer AgidAssociate Professor, Department of Psychiatry, University of Toronto, Toronto, Ontario; Medical Leader, Home Intervention Program, Schizophrenia Program, Centre for Addiction and Mental Health, Toronto, Ontario; Faculty, Institute of Medical Science, Toronto, Ontario.
George FoussiasAssistant Professor, Department of Psychiatry, University of Toronto, Toronto, Ontario; Staff Psychiatrist, Schizophrenia Program, Centre for Addiction and Mental Health, Toronto, Ontario; Scientist, Campbell Family Mental Health Research Institute, Toronto, Ontario.
Gagan FervahaStudent, Institute of Medical Science, Toronto, Ontario.
Hiroyoshi TakeuchiPost-doctoral Fellow, Department of Psychiatry, University of Toronto, Toronto, Ontario; Assistant Professor, Department of Neuropsychiatry, Keio University, Tokyo, Japan.
Jimmy LeePost-doctoral Fellow, Department of Psychiatry, University of Toronto, Toronto, Ontario; Psychiatrist and Consultant, Department of General Psychiatry, Institute of Mental Health, Singapore, Singapore; Assistant Professor, Office of Clinical Sciences, Duke-National University of Singapore Graduate Medical School, Singapore, Singapore.
Margaret HahnAssistant Professor, Department of Psychiatry, University of Toronto, Toronto, Ontario; Staff Psychiatrist, Schizophrenia Program, Centre for Addiction and Mental Health, Toronto, Ontario; Scientist, Campbell Family Mental Health Research Institute, Toronto, Ontario.
Centre for Addiction and Mental Health · CAKeio University · JPNational University of Singapore · SGOntario Institute for Cancer Research · CA

Funding

Canadian Institutes of Health Research
6 · The paper itself

Abstract

objectiveTo examine how advances in our understanding of schizophrenia have shaped thinking about antipsychotics (APs) and their role in treatment.

methodThree specific developments in the field of schizophrenia are highlighted: advances in knowledge related to the earliest stages of schizophrenia, specifically the prodrome; reconceptualization of schizophrenia as an illness of multiple symptom domains; and greater clarification regarding the efficacy of clozapine and a new generation of APs.

resultsEvidence indicating that negative and cognitive symptoms are present during the prodrome suggests that intervention at the time of first-episode psychosis constitutes late intervention. The limited efficacy of APs beyond psychosis argues against a magic bullet approach to schizophrenia and for polypharmacy that is symptom domain-specific. Clozapine's unique, but limited, efficacy in treatment resistance supports subtyping schizophrenia based on treatment response.

conclusionsAdvances in our understanding of schizophrenia have important implications regarding the current use of APs, expectations regarding response, and future drug development.

Indexed as

Prodromal SymptomsTreatment OutcomeAntipsychotic AgentsHumansSchizophreniaAntipsychotic Agents

Identifiers

PMID25886675
PMCPMC4418619
OpenAlexW290470724

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.